Background The lack of an accurate blood biomarker in neuroendocrine tumor (NET)
disease has hindered management. The advance of genomic medicine and the …

Neuroendocrine neoplasms (NENs), also called neuroendocrine tumors (NETs), and
generically referred to as “carcinoids,” represent a spectrum of tumors with a diverse range …

Purpose Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable
neuroendocrine tumors (NETs). Imaging response assessment is usually efficient …

Purpose There are few effective biomarkers for neuroendocrine tumors. Precision oncology
strategies have provided liquid biopsies for real-time and tailored decision-making. This has …

Pancreatic neuroendocrine tumors (PanNENs) are rare sporadic cancers or develop as part
of hereditary syndromes. PanNENs can be both functioning and non-functioning based on …

The NETest is a standardized and reproducible liquid biopsy for neuroendocrine tumors
(NETs). It evaluates the expression of 51 NET genes by real-time polymerase chain reaction …

Background: Management of bronchopulmonary neuroendocrine neoplasia (NEN;
pulmonary carcinoids [PCs], small-cell lung cancer [SCLC], and large cell neuroendocrine …

Background: There are no effective biomarkers for the management of bronchopulmonary
carcinoids (BPC). We examined the utility of a neuroendocrine multigene transcript “liquid …

Background: Identification of circulating tumor markers for clinical management in
bronchopulmonary (BP) neuroendocrine tumors/neoplasms (NET/NEN) is of considerable …

Background Multigene-based PCR tests are time-consuming and limiting aspects of the
protocol include increased risk of operator-based variation. In addition, such protocols are …